Elucida Oncology

Santa Barbara, United States Founded: 2014 • Age: 12 yrs
Nanotechnology-based particle delivery platform is developed for oncology applications.
Annual revenue - Latest available
Total funding $81.5M 4 rounds
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Elucida Oncology

Elucida Oncology is a company based in Santa Barbara (United States) founded in 2014. Elucida Oncology has raised $81.54 million across 4 funding rounds. Elucida Oncology operates in a competitive market with competitors including Abingdon Health, Sirnaomics, Acorda, Liquidia and Genedit, among others.

  • Headquarter Santa Barbara, United States
  • Sectors
    Technology
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Technology → Quantum & Emerging Technologies Unlock Sub-Sector Unlock Segment
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $81.54 M (USD)

    in 4 rounds

  • Latest Funding Round
    $44 M (USD), Series B

    Jan 12, 2021

  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Elucida Oncology

Elucida Oncology has successfully raised a total of $81.54M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $44 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investments & Acquisitions by Elucida Oncology

Investments
Premium access

Investment portfolio details for Elucida Oncology

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Elucida Oncology

Premium access

Detailed financials for Elucida Oncology

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Elucida Oncology Comparisons

Elucida Oncology Primary company
Description
Nanotechnology-based particle delivery platform is developed...
Location
Santa Barbara, United States
Founded Year
2014
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Elucida Oncology

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Elucida Oncology

Elucida Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Sirnaomics, Acorda, Liquidia and Genedit, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of immunoassays for diagnostic purposes
Locked Locked Locked
RNA-based therapeutics for cancer and fibrosis are developed.
Locked Locked Locked
Engaged in the development and commercialization of therapies that improve neurological function.
Locked Locked Locked
Engineered particles & films for life and material sciences applications
Locked Locked Locked
Genetic medicines are delivered using polymer nanoparticle platforms.
Locked Locked Locked
Drug delivery systems to cell interiors are developed via nanosyringes.
Premium access

Detailed competitors of Elucida Oncology

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Elucida Oncology

Premium access

Complete news archive for Elucida Oncology

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Elucida Oncology

Elucida Oncology was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Elucida Oncology is headquartered in Santa Barbara, United States. It is registered at Santa Barbara, California, United States.

Elucida Oncology is a funded company, having raised a total of $81.54M across 4 funding rounds to date.

Elucida Oncology is a developer of a particle delivery platform using nanotechnology. The platform is called ultra-small C dot technology, it encapsulates near-infrared dye with a rigid silica shell which is coated with a layer of polyethylene glycol (PEG). PEG also acts as an ideal linker for a broad variety of ligands. The company claims a 95 clearance of C-dots through the renal system. The company has developed an Image-Guided Sentinel Lymph Node Mapping product, Nanoparticle Drug Conjugates, Nanoparticle Radiotherapeutic Conjugates, Multiplexing: Tumor Nerve Tissue, PET imaging, and others.

Elucida Oncology's top competitors include Sirnaomics, Arcturus Therapeutics and Acorda.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available